Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830140 · ClinicalTrials.gov registry record · Phase 3
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
NCT01830140 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 466 participants.
The verdict
NCT01830140, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
Study Summary
This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
Interventions
- DRUG Bimatoprost 0.03%
- DRUG Bimatoprost 0.01%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01830140
The ClinicalTrials.gov registry entry for NCT01830140 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bimatoprost 0.03% is the first listed.
NCT01830140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01830140 about?
NCT01830140 is a clinical study titled "A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension". This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
What is the current status of trial NCT01830140?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2013-07. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01830140?
The interventions under investigation include: Bimatoprost 0.03% (DRUG), Bimatoprost 0.01% (DRUG).
Who is sponsoring clinical trial NCT01830140?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.